Private company

Stealth BioTherapeutics Corp

Stealth BioTherapeutics Corp is a pharmaceutical preparations company based in George Town, Cayman Islands.²

Last updated Oct 21, 2026.

Overview

-$52.5MNet income, fiscal 2021³

IndustryPharmaceutical Preparations²
HeadquartersGeorge Town, Cayman Islands²
Incorporated inCayman Islands⁴
Business address190 Elgin Avenue, George Town, Grand Cayman, E9 Ky1-9005⁴
Filer categoryNon-accelerated filer, Emerging growth company⁴
Legal formcompany limited by shares²
LEI54930078BE8TT25JE252²
StatusActive²
LEI statusLapsed (not renewed)²
Registered addressC/O Intertrust Corporate Services Cayman Limited, KY1-9005 George Town, Cayman Islands²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

-217.3%Operating margin³

-340.2%Net margin³

-415.4%Return on equity³

0.09×Debt to equity⁵

-$48.1MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2019

Research and developmentInterest

Research and development87¢$44.6M
Interest13¢$6.7M

Out of $21.1M in revenue.³ The company lost money this year.

Financial statements

Operating income⁶⁷⁵³-$45.8M in 2019−26% since 2016

Net income⁶⁷⁵³-$71.7M in 2019+17% since 2016

Fiscal year	2016	2017	2018	2019
Revenue				$21.1M³
Research and development	$48.4M⁶	$63.2M⁷	$53.1M⁵	$44.6M³
Operating expenses
Operating income	-$61.8M⁶	-$79.7M⁷	-$75.3M⁵	-$45.8M³
Interest		$3.3M⁷	$21.4M⁵	$6.7M³
Income before tax
Income tax	$0⁶	$0⁶	$0⁶
Net income	-$61.0M⁶	-$82.9M⁷	-$96.7M⁵	-$71.7M³

Total assets⁶⁷⁵$52.7M in 2019+637% since 2017

Total liabilities⁶⁷⁵$35.5M in 2019−59% since 2017

Shareholders’ equity⁶⁷⁵³$17.3M in 2019

Cash⁶⁷⁵$50.8M in 2019+273% since 2015

Long-term debt⁶⁵$1.5M in 2019−87% since 2017

Fiscal year	2015	2016	2017	2018	2019
Cash	$13.6M⁶	$9.7M⁷	$4.1M⁶	$10.9M⁷	$50.8M⁵
Current assets			$5.9M⁶	$13.3M⁷	$52.4M⁵
Property, plant and equipment
Total assets			$7.2M⁶	$15.5M⁷	$52.7M⁵
Accounts payable
Current liabilities			$24.6M⁶	$40.6M⁷	$34.0M⁵
Long-term debt			$12.0M⁶	$10.3M⁶	$1.5M⁵
Total liabilities			$87.1M⁶	$190.9M⁷	$35.5M⁵
Retained earnings
Shareholders’ equity	-$150.6M⁶	-$209.8M⁷	-$291.3M⁵	-$386.7M³	$17.3M³
Shares outstanding			68.5M shares⁶	68.5M shares⁷	436.7M shares⁷

Cash from operations⁶⁷⁵³-$48.0M in 2019−11% since 2016

Capital spending⁶⁷⁵³$130.0K in 2019−55% since 2016

Free cash flow⁶⁷⁵³-$48.1M in 2019−11% since 2016

Fiscal year	2016	2017	2018	2019
Cash from operations	-$54.0M⁶	-$69.8M⁷	-$72.1M⁵	-$48.0M³
Depreciation and amortization
Stock-based compensation
Capital spending	$287.9K⁶	$161.0K⁷	$12.0K⁵	$130.0K³
Free cash flow	-$54.3M	-$70.0M	-$72.1M	-$48.1M
Cash from investing
Cash from financing

Compare Stealth BioTherapeutics Corp with another company

Corporate structure

Stealth BioTherapeutics Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Stealth BioTherapeutics Corp

Morningside Venture (I) Investments Ltd Filed SC 13D/A on Stealth BioTherapeutics Corp, latest Sep 23, 2022 (4 filings since Dec 10, 2021)
Morningside Venture Investments Ltd Filed SC 13D/A on Stealth BioTherapeutics Corp, latest Nov 22, 2021

Stealth BioTherapeutics Corp George Town, Cayman Islands

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Stealth BioTherapeutics Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, before depreciation	$636.0K³ Dec 31, 2021	$568.0K³ Dec 31, 2020	+12.0%
Accumulated depreciation	$539.0K³ Dec 31, 2021	$462.0K³ Dec 31, 2020	+16.7%
Property and equipment, net	$97.0K³ Dec 31, 2021	$106.0K³ Dec 31, 2020	−8.5%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$47.1M³ Dec 31, 2021	$32.8M³ Dec 31, 2020	+43.8%

Calendar

Drug trials and FDA: coming up

Aug 2027Phase 3 trial readout expected Phase 3 trial of Elamipretide in Age Related Macular Degeneration (ARMD): primary completion expected Aug 2027 (ClinicalTrials.gov NCT06373731).⁸

Drug trials and FDA: recently

Oct 10, 2024FDA advisory committee The FDA's Cardiovascular and Renal Drugs Advisory Committee met to discuss elamipretide hydrochloride injection (NDA 215244), submitted by Stealth BioTherapeutics Inc.⁹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

52 filings to the SEC since October 2021: 1 annual reports, 5 large holders, 46 other. The latest 20:

The 52 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Morningside Venture (I) Investments LtdSC 13D/A, 4 filings Dec 10, 2021 to Sep 23, 2022¹⁰
Morningside Venture Investments LtdSC 13D/A, 1 filing Nov 22, 2021¹¹

SEC filer profile

How Stealth BioTherapeutics Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARStealth BioTherapeutics Corp¹
CIK0001696396
Filer statusNon-accelerated filer<br>emerging growth company¹
Incorporated inCayman Islands¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
Business address190 Elgin Avenue, George Town, Grand Cayman, E9 KY1-9005¹
Phone617-600-6888¹
Shares outstanding712,131,058 as of Dec 31, 2021³
On EDGAR sinceOct 26, 2018¹
Filings138 in all: 6-K (43), SC 13D/A (12), 424B3 (9), CORRESP (9), EFFECT (8), 424B5 (7), UPLOAD (5), 20-F (4)¹
All 29 form types
F-1 (4), F-1/A (4), S-8 (4), S-8 POS (4), POS AM (3), SC 13E3/A (3), CT ORDER (2), D (2), DRS (2), SC 13D (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), F-3 (1), F-6 (1), F-6/A (1), POS EX (1), RW (1), SC 13E3 (1)
Latest filingsAnnual report (20-F) Apr 7, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.